help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

The Oncologist, Vol. 11, No. 9, 981-987, October 2006; doi:10.1634/theoncologist.11-9-981
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldberg, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldberg, R. M.

Special Section on Colorectal Cancer

Therapy for Metastatic Colorectal Cancer

Richard M. Goldberg

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Key Words. FOLFOX • FOLFIRI • Bevacizumab • N9741 • PTK 787 • Cetuximab

Correspondence: Richard M. Goldberg, M.D., CB # 7305, 3009 Old Clinic Building, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. Telephone: 919-966-5720; Fax: 919-966-6735; e-mail: goldberg{at}med.unc.edu

Median overall survival of metastatic colorectal cancer patients treated with first- and second-line combination chemotherapy now extends to more than 20 months in some studies. Chemotherapy alone, particularly when oxaliplatin is included, may allow potentially curative resection of advanced disease. There is evidence that the addition of antibodies targeted against vascular endothelial growth factor or the epidermal growth factor receptor will further improve prospects for patients with advanced and metastatic disease. However, the optimum sequencing of chemo- and biological therapies remains to be established, as does the potential contribution of numerous agents in development.




This article has been cited by other articles:


Home page
 The OncologistHome page
T. McKibbin, C. R. Frei, R. E. Greene, P. Kwan, J. Simon, and J. M. Koeller
Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting
Oncologist, August 1, 2008; 13(8): 876 - 885.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. P. McGahan and V. P. Khatri
Imaging Findings after Liver Resection by Using Radiofrequency Parenchymal Coagulation Devices: Initial Experiences
Radiology, June 1, 2008; 247(3): 896 - 902.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Gao, D. K. Price, T. Sissung, E. Reed, and W. D. Figg
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1
Mol. Cancer Ther., May 1, 2008; 7(5): 1246 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Benesch, M. Windelberg, W. Sauseng, V. Witt, G. Fleischhack, H. Lackner, H. Gadner, U. Bode, and C. Urban
Compassionate use of bevacizumab (Avastin(R)) in children and young adults with refractory or recurrent solid tumors
Ann. Onc., April 1, 2008; 19(4): 807 - 813.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Johnston
The Colorectal Cancer Coalition: Reflections on the Future
Oncologist, October 1, 2006; 11(9): 970 - 972.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.